CTX121

Serial Number 97461207
602

Registration Progress

Application Filed
Jun 16, 2022
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: CTX121
Previous Owner: CRISPR Therapeutics AG
Classes: 005, 042

Trademark Image

CTX121

Basic Information

Serial Number
97461207
Filing Date
June 16, 2022
Abandonment Date
May 16, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
May 31, 2023
Classes
005 042

Rights Holder

CRISPR Therapeutics AG

99
Address
Baarerstrasse 14
ZUG V8 SWITZERLAND 6300
CH

Ownership History

CRISPR Therapeutics AG

Original Applicant
99
ZUG V8 SWITZERLAND CH

Legal Representation

Attorney
Tiffany D. Gehrke

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

9 events
Date Code Type Description Documents
May 31, 2023 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
May 31, 2023 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
May 31, 2023 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Feb 14, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Feb 14, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 14, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 7, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 30, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 20, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Pseudo Mark
CTX ONE TWO ONE; CTX ONE HUNDRED TWENTY ONE

Classification

International Classes
005 042